Integrated with SynNotch recognizingan introduced and clinically validated antigen CD19 expressed on asubset of cancer cells as “training centers”, CD19-SynNotchPDbody-CAR T cells were further applied to target the whole populationof cancer cells expressing PD-L1. This evidence concerns the gene CD19 and cancer.